Key result
Ivabradine therapy successfully reduced heart rate to 59 bpm and improved left ventricular diastolic function over 12 months in a patient with ischemic heart failure with preserved ejection fraction.
Why the study?
Heart rate-reducing therapy in ischemic chronic heart failure can be difficult due to beta-blocker side effects, intolerance, or contraindications in severe comorbid pathology.
Case Report (n=1)
Ivabradine combined with beta-blockers may be an effective heart rate-reducing strategy in patients with ischemic HFpEF.
Answers are grounded in this paper and cite their sources.
May support beta-blocker use in chronic HF; leaves open confirmation in randomized trials.
Chronic heart failure is one of the leading causes of mortality among patients with cardiovascular diseases. Current therapeutic methods for treating patients with chronic heart failure do not always provide a significant improvement in main intermediate and final outcomes. According to the neurohumoral theory of chronic heart failure development, an antagonism of the sympathoadrenal system with b-blockers is pathogenetically substantiated, and the drugs of this group are one of the first-line treatment for chronic heart failure. The selection of heart rate-reducing therapy in patients with chronic heart failure caused by ischemia, can often be difficult due to development of b-blockers side effects, b-blockers intolerance and/or due to the presence of contraindications at severe comorbid pathology. This article presents a clinical case of an effective administration of ivabradine, a drug of if-channel inhibitors group, in combination with b-blockers to a patient with chronic heart failure with a preserved ejection fraction.
No takes yet. Share an insight, caveat, or question.
Belenkov et al. (2019) conducted a case report in Ischemic chronic heart failure with preserved ejection fraction and hereditary thrombophilia (n=1). Ivabradine was evaluated on Heart rate and left ventricular diastolic function (E/A ratio). Ivabradine therapy successfully reduced heart rate to 59 bpm and improved left ventricular diastolic function over 12 months in a patient with ischemic heart failure with preserved ejection fraction.
Synapse has enriched 10 related papers. Consider them for comparative context: